JERSEY CITY, N.J., June 11, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ:SCYX), a biotechnology company developing innovative
therapies for difficult-to-treat and often life-threatening
infections, today announced the presentation of data at American
Society for Microbiology (ASM) Microbe 2018, June 7-11, 2018, in Atlanta. SCY-078, the first representative of
a novel oral and intravenous (IV) triterpenoid antifungal family,
is in clinical development for the treatment of multiple serious
fungal infections, including vulvovaginal candidiasis, invasive
candidiasis, invasive aspergillosis and refractory invasive fungal
infections.
"The data presented at ASM Microbe showcase the potent in
vitro activity of SCY-078 across a range of Candida
strains, including echinocandin-resistant strains, as well the
in vitro synergistic activity of SCY-078 with isavuconazole
against numerous Aspergillus spp., providing further support
to our ongoing and planned clinical programs, specifically FURI,
CARES and Aspergillus combination studies," said
David Angulo, M.D., Chief Medical
Officer of SCYNEXIS. "The synergistic activity of SCY-078 against
Aspergillus spp. has the potential to improve outcomes in
this difficult-to-treat infection, and the distinct changes that
SCY-078 induced in the cellular morphology of Candida
strains, when compared to echinocandins, illustrate the
differentiated effect of this novel triterpenoid antifungal
compound, a critical feature when addressing the growing concern of
multidrug-resistant fungal infections."
Poster Title: Morphological Effect of SCY-078 and
Caspofungin on Different Echinocandin-Resistant Candida
Species
The poster describes the results from a study designed to
evaluate in vitro, morphological changes when Candida
albicans, C. auris or C. glabrata are exposed to
SCY-078, as compared to caspofungin and untreated control. The
morphological findings in this study show the activity of SCY-078
against these Candida species, and clearly show the activity
of SCY-078 is distinguished from the echinocandins based on the
results against echinocandin-resistant isolates.
Poster Title: In Vitro Activity of SCY-078 in
Combination with Isavuconazole or Amphotericin B against Medically
Important Moulds
The poster describes the results from a study designed to
evaluate the in vitro activity of SCY-078 with isavuconazole
or amphotericin B against Aspergillus spp., Scedosporium
apiospermum and Mucorales. The findings in this study show the
synergistic activity of SCY-078 and isavuconazole against all
evaluated Aspergillus spp., with the greatest synergistic
activity demonstrated against A. fumigatus. These results
indicate that the combination of SCY-078 and mold-active azoles has
the potential to serve as an efficacious treatment for invasive
aspergillosis and support additional investigation.
Poster Title: Does Sabouraud Dextrose Broth, Compared to
RPMI, Differentiate Susceptibility between Resistant and
Susceptible Candida glabrata and C. albicans
Isolates to SCY-078, a Novel β-D-Glucan Synthase Inhibitor, and
Caspofungin?
The poster describes the results from a study designed to
evaluate the ability of Sabouraud dextrose broth to identify the
susceptibility of C. glabrata and C. albicans to
SCY-078, caspofungin and micafungin. These results show that
minimum inhibitory concentrations (MIC) for SCY-078 and caspofungin
were lower in Sabouraud dextrose broth than in RPMI, a standard
medium employed for this determination. This data shows that
Sabouraud dextrose broth may be more effective for determining the
susceptibility of strains to SCY-078 and caspofungin.
All presentations are available on the Scientific
Publications page of the SCYNEXIS website.
About SCY-078
SCY-078 is an
investigational antifungal agent that is a semi-synthetic
derivative of the natural product enfumafungin. SCY-078 is the
first representative of a novel class of structurally-distinct
glucan synthase inhibitors, triterpenoids. This agent combines the
well-established activity of glucan synthase inhibitors with the
potential flexibility of having IV and oral formulations. SCY-078
is currently in development for the treatment of fungal infections
caused primarily
by Candida (including C. auris)
and Aspergillus species. It has demonstrated broad
spectrum antifungal activity, in
vitro and in vivo, against multidrug-resistant
pathogens, including azole- and echinocandin-resistant strains.
The FDA has granted QIPD and Fast Track designations for
the formulations of SCY-078 for the indications of invasive
candidiasis (IC) (including candidemia), invasive
aspergillosis (IA), and VVC, and has granted Orphan Drug
Designation for the IC and IA indications.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a
biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often
life-threatening infections by developing innovative therapies.
The SCYNEXIS team has extensive experience in the
life sciences industry, discovering and developing more than 30
innovative medicines over a broad range of therapeutic areas. The
Company's lead product candidate, SCY-078, is a novel IV/oral
antifungal agent in Phase 2 clinical and preclinical development
for the treatment of multiple serious and life-threatening invasive
fungal infections caused
by Candida and Aspergillus species.
For more information, visit www.scynexis.com.
CONTACT:
Investor
Relations
Susan Kim
Argot Partners
Tel: 212-600-1902
susan@argotpartners.com
Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-presents-scy-078-data-at-asm-microbe-2018-300660106.html
SOURCE SCYNEXIS, Inc.